NICE recommends multimodal antidepressant for depressive episodes

Vortioxetine (Brintellix) has been approved by NICE as a possible treatment for adults having a first or recurrent major depressive episode that has not responded to 2 antidepressants.

Vortioxetine can now be prescribed on the NHS for patients with depression meeting certain conditions. | WELLCOME DEPT. OF COGNITIVE NEUROLOGY/ SCIENCE PHOTO LIBRARY
Vortioxetine can now be prescribed on the NHS for patients with depression meeting certain conditions. | WELLCOME DEPT. OF COGNITIVE NEUROLOGY/ SCIENCE PHOTO LIBRARY

Patients who were already started on vortioxetine before the new guidance was issued but do not meet the specified conditions should be able to continue treatment until their clinician deems it appropriate to stop. 

Vortioxetine is thought to modulate several neurotransmitter pathways including serotonin, GABA, noradrenaline and dopamine. These different modes of action are believed to be responsible for the cognitive, learning and memory improvements seen in animal studies of the drug.

Further information
NICE technology appraisal TA367

As with all antidepressants, treatment should continue for at least 6 months after symptoms resolve.

GI upset, pruritus, dizziness and abnormal dreams are the most common adverse effects of vortioxetine. Studies have shown that vortioxetine does not increase the incidence of somnolence or insomnia relative to placebo. In both short- and long-term studies vortioxetine had no effect on weight, heart rate or blood pressure compared with placebo. 

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Table: Antidepressants, a Guide to Switching and Withdrawing

Instructions for changing or stopping antidepressants.

Infographic: Inappropriate prescribing of antidepressants in children and adolescents

Infographic: Inappropriate prescribing of antidepressants in children and adolescents

Prescribing of antidepressants in children and adolescents...

MIMS guidance on switching and withdrawing antidepressants updated

MIMS guidance on switching and withdrawing antidepressants updated

Advice on switching and withdrawing antidepressants...

Vortioxetine: New for depressive episodes

Vortioxetine: New for depressive episodes

Brintellix (vortioxetine) is indicated for the treatment...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases